¼¼°èÀÇ ¿ä³×º´ Áø´Ü ½ÃÀåÀº 2023³â¿¡ 6¾ï 4,560¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£ÀÇ CAGRÀº 5.2%·Î È®´ëµÉ °ÍÀ¸·Î Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù.
ÀÌ ¼ºÀåÀº ¿ä³×º´¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡¿Í °¡ÃàÀÇ °Ç°°ú »ý»ê¼º¿¡ ¹ÌÄ¡´Â ¿µÇâÀÌ Å®´Ï´Ù. ¿ä³×º´Àº ¸¶ÀÌÄÚ¹ÚÅ׸®¿ò ¾Æºñ¿ò ¾ÆÁ¾ ÆÄ¶óÃ÷º£¸£Å¬·Î½Ã½º(MAP)¿¡ ÀÇÇØ ¹ß»ýÇÏ¸ç ¼Ò, ¾ç, ¿°¼Ò°¡ ÀÌȯµÇ´Â ¸¸¼º À§Àå °¨¿°º´ÀÔ´Ï´Ù. °¡Ãà »ý»êÀÚµéÀÌ ÀÌ Áúº´ÀÇ °æÁ¦Àû ¿µÇâÀ» ´õ °ÇÏ°Ô ÀνÄÇÔ¿¡ µû¶ó È¿°úÀûÀÎ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
ÃÖ±ÙÀÇ Åë°è¿¡¼´Â ¿ä³×½ºº´ÀÌ ³Î¸® ¸¸¿¬ÇØ, Ãà»ê¾÷¿¡ Å« °æÁ¦Àû ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ´Â °ÍÀ» °Á¶µÇ°í ÀÖ¾î, ¼±ÁøÀû Áø´Ü ¹æ¹ýÀÇ Çʿ伺ÀÌ °Á¶µÇ°í ÀÖ½À´Ï´Ù. PCR°ú Ç÷ûÇÐÀû °Ë»ç µî Áø´Ü ±â¼úÀÇ Áøº¸·Î °ËÃâÀÇ Á¤È®µµ¿Í ¼Óµµ°¡ Å©°Ô Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °³·®¿¡ ÀÇÇØ Áø´Ü ±â¼úÀº ¼öÀǻ糪 °¡Ãà ¼ÒÀ¯ÀÚ¿¡°Ô ´õ ¸Å·ÂÀûÀÎ °ÍÀÌ µÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ µ¿¹° º¹Áö¿Í Áö¼Ó°¡´ÉÇÑ ³ó¹ýÀÌ Á߽õʿ¡ µû¶ó, °¨¿° °¡ÃàÀ» È¿°úÀûÀ¸·Î ƯÁ¤ ¹× °ü¸®Çϱâ À§ÇÑ ½Å·Ú¼º ³ôÀº Áø´Ü¹ýÀÇ Ã¤¿ëÀÌ ÇÑÃþ ´õ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.
ÀÌ·¯ÇÑ ¿äÀÎÀÌ °áÇյǾî, ¿ä³×º´ Áø´Ü ½ÃÀåÀº Ç÷¯½º ¼ºÀåÀ» °è¼ÓÇϰí ÀÖ½À´Ï´Ù. ¿ä³×º´ Áø´ÜÀº Ç×ü¸¦ µ¿Á¤ÇÏ´Â È¿¼Ò°áÇո鿪ÈíÂøÃøÁ¤¹ý(ELISA)°ú ºÐº¯ »ùÇà Áß MAP DNA¸¦ °ËÃâÇÏ´Â ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR) µî MAP¸¦ °ËÃâÇϱâ À§ÇÑ ´Ù¾çÇÑ ¹æ¹ýÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. Á¶±âÀÇ Á¤È®ÇÑ Áø´ÜÀº Áúº´ÀÇ ¸¸¿¬À» ¾ïÁ¦ÇÏ°í °æÁ¦Àû ¼Õ½ÇÀ» ÃÖ¼ÒÈÇϱâ À§ÇØ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. °Ë»ç À¯Çüº°·Î´Â PCR ºÎ¹®ÀÌ 2023³â 45.3%·Î ÃÖ´ë ½ÃÀåÁ¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ´Â °ÍÀº, ³ôÀº Á¤¹Ðµµ, °¨µµ, MAP¸¦ Á¶±â ´Ü°è¿¡¼ °ËÃâÇÏ´Â ´É·ÂÀÔ´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ³â | 2023³â |
¿¹Ãø³â | 2024-2032³â |
½ÃÀÛ °¡°Ý | 6¾ï 4,560¸¸ ´Þ·¯ |
¿¹»ó °¡°Ý | 10¾ï ´Þ·¯ |
CAGR | 5.2% |
PCR ±â¼úÀÇ Çõ½ÅÀº ¶ÇÇÑ ¼öÀÇ Áø´ÜÀ» À§ÇÑ PCRÀ» º¸´Ù Ä£¼÷ÇÏ°í ºñ¿ë È¿À²ÀûÀÎ °ÍÀ¸·Î ¸¸µé°í ±× º¸±Þ¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¿ä³×º´ÀÌ °¡Ãà »ý»ê¼º¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ Áõ°¡ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ PCR ºÎ¹®ÀÇ ÁöÀ§¸¦ ´õ¿í °ß°íÇÏ°Ô ¸¸µì´Ï´Ù. µ¿¹° À¯Çüº°·Î 2023³â ½ÃÀå ±Ô¸ð´Â 5¾ï 8,170¸¸ ´Þ·¯·Î ¾Ï¼Ò ºÎ¹®ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áúº´Àº Á¥¼Ò ±ºÀ¸·Î ¸¸¿¬Çϱ⠶§¹®¿¡ ¿ìÀ¯ »ý»ê, üÁß ¹× Àü¹ÝÀûÀÎ °Ç°¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ÁÙÀÌ´Â Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô½À´Ï´Ù. ÀÌ·¯ÇÑ Á¶±â ¹ß°ßÀÇ Çʿ伺ÀºÀÌ ºÎ¹®¿¡¼ Áø´Ü ¾à¹°ÀÇ ¼ºÀåÀ» Áö¿øÇÕ´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ¿ä³×º´ Áø´Ü ½ÃÀåÀ» °ßÀÎÇØ, 2023³â ½ÃÀå ±Ô¸ð´Â 2¾ï 7,180¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£ÁßÀÇ CAGRÀº 5.1%·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀÇ ¼±ÁøÀû ¼öÀÇÇÐÀû ÀÎÇÁ¶ó, »ý»êÀÚÀÇ ÀÇ½Ä Çâ»ó, Áúº´ °ü¸®¸¦ À§ÇÑ °ß°íÇÑ ±ÔÁ¦ ƲÀÌ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹Ý¸é ¹Ì±¹ ½ÃÀåÀº 2023³â 2¾ï 4,870¸¸ ´Þ·¯¸¦ Â÷ÁöÇÏ¿´°í, 2032³â¿¡´Â 3¾ï 8,090¸¸ ´Þ·¯·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ´Â Á¤ºÎÀÇ °·ÂÇÑ ÀÌ´Ï¼ÅÆ¼ºê¿Í PCR, ELISA µîÀÇ ¼±Áø Áø´Ü¹ýÀÇ º¸±Þ¿¡ ÁöÁöµÇ°í ÀÖ½À´Ï´Ù.
The Global Johnes Disease Diagnostics Market, valued at USD 645.6 million in 2023, is projected to expand at a CAGR of 5.2% over the forecast period. This growth is largely attributed to increasing awareness of Johnes disease and its impact on livestock health and productivity. Johnes disease, caused by Mycobacterium avium subspecies paratuberculosis (MAP), is a chronic gastrointestinal infection that affects cattle, sheep, and goats. As livestock producers become more aware of the financial repercussions of this disease, the demand for effective diagnostic solutions is rising.
Recent statistics highlight the widespread prevalence of Johnes disease and its significant economic impact on the livestock industry, underscoring the need for advanced diagnostic methods. Technological advancements in diagnostics, such as PCR and serological tests, have significantly improved the accuracy and speed of detection. These improvements are making diagnostic techniques more appealing to veterinarians and livestock owners. Moreover, the emphasis on animal welfare and sustainable farming practices has further driven the adoption of reliable diagnostic methods to identify and manage infected livestock effectively.
Together, these factors are contributing to the positive growth trajectory of the Johnes disease diagnostics market. Johnes disease diagnostics employ various methods to detect MAP, including the Enzyme-Linked Immunosorbent Assay (ELISA), which identifies antibodies, and the Polymerase Chain Reaction (PCR) test, which detects MAP DNA in fecal samples. Early and accurate diagnosis is critical for controlling disease spread and minimizing economic losses. By test type, the PCR segment held the largest market share at 45.3% in 2023. This segment's growth is driven by its high accuracy, sensitivity, and ability to detect MAP at early stages.
Market Scope | |
---|---|
Start Year | 2023 |
Forecast Year | 2024-2032 |
Start Value | $645.6 Million |
Forecast Value | $1 Billion |
CAGR | 5.2% |
Innovations in PCR technology have also made it more accessible and cost-effective for veterinary diagnostics, which has fueled its popularity. The increasing awareness of Johnes disease's impact on livestock productivity and the demand for reliable diagnostic tools have further strengthened the PCR segment's position. In terms of animal type, the cattle segment dominated the market with a value of USD 581.7 million in 2023. Due to the disease's prevalence in dairy herds, there is a high demand for diagnostic solutions to mitigate the disease's effects on milk production, weight, and overall health. This need for early detection supports the growth of diagnostics in this segment.
Regionally, North America led the Johnes disease diagnostics market, valued at USD 271.8 million in 2023, with an anticipated CAGR of 5.1% during the forecast period. The region's advanced veterinary infrastructure, increased awareness among producers, and robust regulatory frameworks for disease control are key growth drivers. Meanwhile, the U.S. market accounted for USD 248.7 million in 2023, with a projected increase to USD 380.9 million by 2032, supported by strong government initiatives and the widespread use of advanced diagnostics like PCR and ELISA.